Shares of Splash Beverage Group (SBEV) experienced a significant rally on Wednesday, closing up 71.0% at $0.2420, and continued to climb in premarket trading on Thursday, reaching $0.3650 before the NYSE American opened. The surge followed the company's announcement that it had submitted a plan to regain compliance with the exchange's stockholders' equity listing requirements.
The compliance plan, filed on May 28, comes in response to a notification from NYSE Regulation on April 29 that Splash had fallen out of compliance with listing standards related to stockholders' equity—essentially assets minus liabilities. If the exchange accepts the plan, the company could be granted a cure period extending to January 29, 2027, providing a crucial lifeline to avoid delisting.
However, the rally is driven more by survival maneuvers than by any uptick in beverage sales. Splash's balance sheet remains under significant pressure. For the first quarter, the company reported net revenue of just $4,224, a sharp decline from $68,606 in the same period last year. Net loss from continuing operations stood at $2.14 million, underscoring the financial strain.
Cash and cash equivalents as of March 31 totaled only $381,195, which management acknowledged is insufficient to cover working capital needs for the next twelve months. Additionally, a non-binding letter of intent with Medterra CBD expired on May 4 without resulting in a definitive agreement, leaving Splash's cannabinoid wellness strategy dependent on new negotiations and fresh financing. The company had previously indicated it needed approximately $10 million to fund the Medterra deal.
Interim CEO Brady Cobb described the NYSE compliance plan as an "important milestone" and emphasized that the company is moving forward on multiple fronts. He stated that any potential partnership must be both "strategically compelling" and "financially responsible." Splash is currently in talks with several other potential partners in the cannabinoid wellness space, though no agreements have been finalized.
The company's product portfolio remains limited, with its sole revenue-generating line being Chispo tequila, sales of which were primarily directed to Señor Frog locations during the first quarter. Splash has noted that sluggish beverage sales have prompted a strategic shift toward regulated wellness and cannabinoid markets, aiming to compete with larger players like Tilray Brands and Canopy Growth, though from a much smaller and financially constrained position.
Investors should be aware of the significant risks involved. The NYSE American could still reject the compliance plan, negotiations with potential partners may not yield a signed deal, and any capital raising efforts could result in dilution for existing shareholders. The company itself lists these uncertainties in its filings, including the need for additional funding, maintaining its listing, executing strategic transactions, and navigating evolving cannabinoid regulations.
The next key event will be whether the premarket buying momentum holds once regular trading begins at 9:30 a.m. Eastern. Ultimately, Splash must demonstrate that its compliance plan and ongoing deal discussions can translate into the equity, cash, and operational improvements necessary to secure its listing and long-term viability.
